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A clone encoding the rat type II Fey receptor was isolated from a cDNA library of the rat mucosal mast cell line RBL-2H3 and its sequence 
determined. The predicted amino acid sequence is highly homologous with the mouse type II as well as rat type III Fey receptors. The site of 
alternative splicmg which generates the mouse FcyRb? lsoform is completely conserved. Hence we consider the new sequence to encode a rat FcyRlI 
b2 lsoform. In further analogy to the mouse receptor. no consensus motif known to be mvolved m accessory chain assoclatlon was observed m 
the trdnsmembranal domain. The Importance of the ldentificatlon of this receptor for mvestigatlon of the immunological stimulation of mast cells 
1s dlscussed. 
Fey receptor. RBL-2H3: Mast cell 
1. INTRODUCTION 
Receptors for the Fc domain of immunoglobulins 
(FcR) have been described for every Ig isotype. They 
provide an essential control and feedback link between 
the specific humoral and cell-mediated immune re- 
sponses. This explains the fact that FcRs are found on 
all cell types of the immune system. In many cases sev- 
eral distinct Fc receptors are observed on one cell type. 
The most widely distributed FcRs are those for the 
Fc domain of IgG (FcyR). The common structural fea- 
ture of all Fc receptors (with one exception of FceRII 
[l]) is an extracellular ligand binding unit containing 
two or three Ig-like domains [2]. Therefore they belong 
to the immunoglobulin superfamily [3]. Three main 
types of FcyR have been recognized in man and mouse 
[3]; FcyRI, FcyRII and FcyRIII. The type I Fey recep- 
tor binds monomeric IgG, types II and III, however, 
have lower affinity for IgG, hence they only bind its 
aggregates, i.e. immune complexes. Polymorphism in 
the ligand binding subunit of each type is considerable 
yet the main region of variability is the cytoplasmic tail. 
Altogether there are at least 12 different isoforms in 
human (for a review see [4]) with strictly controlled cell 
type expression. Studies aimed at resolving the sig- 
nailing motifs of particular isoforms yield growing evi- 
dence for functional relevance of the extensive struc- 
tural diversity. Only FcyRII has so far been found as 
a single chain receptor. The other FcyRs contain non- 
covalently associated accessory chains such as y [5] or 
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The studies of the type I FCE receptor, the principal 
receptor of mast cells and basophils, were pioneering 
and provided major advances in our understanding of 
the structure and function of Fc receptors. Thus rat 
mast cells, specifically those isolated from the perito- 
neum and the mucosal type line RBL-2H3, are those 
most widely employed as the experimental model sys- 
tems for investigating the Fc&RI structure and its cou- 
pling cascade to the mast cell function, e.g. the secretory 
response [IO]. The capacity of RBL-2H3 cells to bind 
IgG class antibodies has been reported [l 11. Further, a 
membrane component, distinct from FceRI and 
Fc&RII, binding rat IgE with low-affinity has been ob- 
served on rat mast cells (including RBL-2H3 cells) [ 121. 
On human and mouse mast cells the presence of several 
isoforms of the low-affinity Fey receptors is known [13] 
and recent studies [14] showing their binding capacity 
also for IgE could rationalize the above result. How- 
ever. the FcyRs on rat mast cells, particularly RBL-2H3 
cells, have so far not been even structurally defined. 
Thus unequivocal determination of the types and struc- 
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6 [6] (originally identified in FceRI and the CD3 com- 
plex, respectively) responsible, in the case of FcyRIII, 
for the signal transduction and membrane expression 
[7]. The rodent FcyRs system is clearly less complex 
than its human counterpart and therefore serves as a 
good experimental model in the effort towards under- 
standing FcyRs structure - function relations. Rat Fey 
receptors have so far been less well characterized than 
those of the mouse. Rat FcyRIII has been cloned [S] 
and found. surprisingly. to be a family of homologous 
isoforms not encountered in the mouse [9]. The se- 
quences of other rat FcyRs have not yet been deter- 
mined. 
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tures of rat mast cells Fey receptors is required. Here 
we report cloning of the rat FcyRII from RBL-2H3 
cells. We provide evidence that in analogy to the mouse 
FcyRII, this clone is a b2 isoform of rat FcyRII. 
2. MATERIALS AND METHODS 
2.1. Preparatton qf the probe by the po!vmerase chain reaction 
The probe for the rat cDNA library screening was prepared using 
the polymerase chain reaction on rat cDNA. The design of PCR 
pnmers was based on comparisons of cDNA sequences of mouse and 
human FcyRII in order to identify the most conserved stretches (Gen/ 
EMBL: mouse m14216.em_ro, m31312,em_ro, m17515.em_ro and 
human m28696.em_pr. x 52473.em_pr, m31935.em_pr). Multiple se- 
quence alignments were carried out using the University of Wisconsin 
GCG software package [15]. Two the most conserved regions show- 
ing, however, the least homology to the rat FcyRIII (GenlEMBL 
m64370) were chosen for the synthesis of primers (forward 
primer = base pairs 104-123 and reverse primer = antIsense to 714 
733 in mouse ml4216,em_ro). The PCR amplification was performed 
usmg random primed cDNA of RBL-2H3 cells (provided by Dr. M. 
Tal) and the con&ions were as follows: 94°C. 1 min; 55°C. 2 min; and 
72°C 3 min in 34 cycles plus 10 min final extension at 72°C. The 
product of the reaction (approximate length 650 bp) was purified 
(DS-Primer Remover - Adv. Gen. Tech. Corp.), treated with Klenow 
enzyme (Boehringer) and subcloned into the SmuI site of a plasmId 
vector (BSII KS+/- Stratagene) for sequence analysis. Direct auto- 
matic dye-terminator sequencing (Applied Biosystems-AB 373A 
DNA sequencer) confirmed the expected high homology of the prod- 
uct (629 bp) to the mouse FcyRII. The subcloned product of the PCR 
amplification was excised from the plasmid and isolated after electro- 
phoresis in low melting agarose. The insert was labeled (random pnm- 
ers labeling kit Boehringer) with adATP (Amersham) and used in 
the following library screening as well as Southern blotting. 
2.2. Rat cDNA Irbrary screening and DNA sequencing 
The rat cDNA library from RBL-2H3 cells was provided by Dr. M. 
Tal and M. Guthmann (Weizmann Institute). It was built using 
pcDNA I plasnud (Invitrogen. San Diego) in the MC1061/P3 E. coli 
strain Forty-eight pools each of 10’ were subjected to PCR amplifica- 
tion with the same primers and conditions as used for probe prepara- 
tlon. Products were resolved on agarose gels and positive clones de- 
tected by Southern blotting (using Hybond N+ membranes-Amer- 
sham). Positive pools were screened by colony hybridization using 
stringent washing conditions (washing temp. 65°C. 0.2 SSC). Six pos- 
itive clones were isolated and the length of Inserts analyzed by agarose 
electrophoresis. The clone with the longest insert was selected and 
both DNA strands completely sequenced by direct automatic dye- 
terminator sequencmg (Applied Biosystems -AB 373A DNA se- 
quencer). 
2.3. Sequence analysrs 
Analysis of the obtained DNA sequence was carried out usmg GCG 
software package [15]. DNA sequence was compared to the Gen/ 
EMBL database and amino acids sequence to the NBRF and Swiss- 
Prot databases. 
3. RESULTS 
The probe for screening the rat cDNA library for 
FcyRII was prepared on the basis of a comparing 
cDNA sequences of known mouse and human FcyRII 
isoforms. The high homology among the extracellular 
domains (EC) of mouse and human type II and 111 
FcyRs sequences is contrasted by marked differences in 
their transmembrane (TM) and cytoplasmic (IC) do- 
mains. We assumed this also holds for the rat. The 
probe was designed so as to contain stretches of the TM 
or IC regions in order to allow resolution between type 
II and known type III FcyRs. The PCR was used to 
amplify the sequence to be employed as a probe. Com- 
parison of the human and mouse FcyRII cDNA se- 
quences identified the most conserved stretches. We se- 
A moFcyRI1 83 GTTCTCACGGACTTTGTGCC ATGCTACTGTGGACAGCC 
II I I I I III I I I IIIII IIIIIIIIIIl 
huFcyRI1 101 GTCCCCCCAGCCTTGGGGTC ATGCTTCTGTGGACAGCT 
674 CAGGTCTTTACCAGTATTGACAATTGTGGCTGCTGTCAC 
III III1 III I II IIIIlIIIII 
692 CAGCTCTTCACCGATGGGGATCATTGTGGCTGTGGTCAC GGACTGCTG 741 
B 
Fig. 1. Oligonucleotide sequences employed as PCR primers. In A. parts of the cDNA sequence of mouse FcyRII (GenlEMBL m14216.em_ro) 
are aligned with homologous regions of the human FcyRII (GenlEMBL m28696.em_pr). In B, the same regions of the mouse FcyRII sequence 
are aligned with the respective rat FcyRIII regions (Gen/EMBL m64370) Olrgonucleotides syntheslsed as PCR primers are framed (forward primer 
_ base pairs 104-123 and reverse primer - antlsense to 71&733 in mouse FcyRII Gen/EMBL m14216.em_ro). 
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121 CCCCATGtACAGCAACAGGACX GTCGTCCATGTGCTCTCACGGACT166 
-33 MDSNRTVVHVLSRT -20 
167 TTG TAC CAT ATG CTA GIG TGG ACA GCT GTG CTA AAT CIT GTT GCT 211 
-19LYHMLLWTAVLNLVA -5 
212 GAG TCT CAT GGT CITCCGAAGGCT G'IGGTGAAACIT GAGCCC 256 
-4E S H i?G L P K A V V K L E P 11 
257 CCA TGG ATC CAG GTG CIT AAG GAA GAC ACT GTG ACA CCG An; TGC 301 
l2P WI QVLK E D TVTL M @ 26 
302 GAAGGGACCCACAACACCAAGAAC TiZ TCTACTCAG TGGTIT CAC 346 
27E G T H N T K[N C SIT Q W F H 41 
347 AAT GGG AGC TCC ATC TGG CAT CAA GCC CAA GCC AAC TAC ACG TTT 391 
42(N-1 S I W H Q A Q A-F56 
392 AAGGCCACAGTCAAT GAT AGTCGA GAA TACCGGTGC CZAATGGAG 436 
57K A T V[v G E Y R@RME 71 
437 GAG ACC GGC ATC AGC G&A CCC ATA CAT CX CGA GTG ATT TCT GAC 481 
72ETGISEPIHLGVISD 86 
482 TGGCTGCTACTC CAGACC TCTCAACTGGIGTTTGAA GAAGGGGAA 526 
87W LLLQ T S Q LVE'E EGE 101 
527ACCATCACATTAAGGTCCCATAGCTGGAAGAACAPACAGC-XACT 571 
102 T I T L ROHSWKNKQLT 116 
572 AAGGIC TTGTTG'ITC CAGAATGGAAAAC~GTGAGGTAT TAT CAT 616 
ll7KVLLF QNGKPVRYYH 131 
617 CAA AGC AGC AAT TTT TCA ATC CCC AAA GCC AAC CAC AGT CRC ACT 661 
132 Q S S IN F Sj I P K A[-HS 146 
662 GGG AAC TAC TAT TGC AAA GCA TAT CTA u;A AGG ACA ATG CAC GTG 706 
147 G N Y Y@KAYL G.R T M H V 161 
707 TCC AAG CCT GTC ACC A'IC ACT GTC CAA GAG CCC AAA 'ICC ACZ AGT 751 
162s KPVT I TVOEPKSSS 176 
752 TCG TX CCG Gl'A TTG ACG ATT GTA & -& i'TC -&'C &A i&T &T %I6 
177s LPVLT I VAAVAG IA 191 
197 Gl?A GCI'GCC ATT GTT ATT ATC CTG Gl'A TCC TTGGTC TAT C?X AAG a41 
l92VAAIV I I L V S L V YLK 206 
842AAAAAGCAGGTPCCACACACTCCTTCTGGTCTCGAACAAGCTC4G a86 
207KKQVP D TP S GLEE A E 221 
a87 AAAAAT GAGGTGGAGAATACAATCACC TAT TCACTT CTC AAGCAT 931 
222K N E V E N T -I T Y S L L K W 236 
932 'Xl GAA GCTCCG GAT GAAGAATCAGAT CAC GACTAC CAGAAC CAC 976 
237P EAP D EE S DHDYQNH 251 
977ATp TAGTCICTCTTCAGA mGCAAACcA!x AAGGCCAGGACCTAGCGXTC 1034 
252 I * 
1035 CTGGTCCAAGO\ATrXJTGA~TATGAAAGAAARCATC 1094 
1095GAAACULACAtACACTACGAT~ CCCAATGGTTGACTGGACITCCATA 1154 
1155 ACTTACAGCIX C~~~CmTCCTATAGATCCACACACCCAAT1214 
1215 TCAACTTACK;TPGTPAAGACACTA~A~~~G 1274 
1275 G~T~~~~~T~~A~~~A~~ 1334 
1335 TGTCAAA~G~W~TGCITCGAAACI-~=TATTT~AT-ITTXTAT AAA!zGrCAc 1394 
1395 ATATTACTTITATA GTAAUTGl-.XTGA.UATGTCCAAAAAAAAAAAAAAAAAA 1448 
Fig 2. Rat FcyRII. (a) Scheme of the cloned cDNA open rectangles indicate codmg region - sIgnal peptide (SP)? extracellular (EC). transmem- 
branal (TM) and intracellular (IC) regions Partial restrictlon map and the sequencing strategy is presented. (b) Nucleotide and translated amino 
acid sequences of the cloned cDNA Translated sequence 1s presented in the one letter code. A signal peptide is predIcted, cleavage site indicated 
by a bar between -1 and 1. N-Linked glycosylatlon sites are framed, cystein residues crrcled. predicted TM region overhned 
lected those two which showed a low level of homology 
with rat FcyRIII. These sequences were then used to 
prepare the primers for PCR amplification (Fig. 1). 
Wherever the mouse and human DNA sequences dif- 
fered, that of the mouse was used. The PCR amplifica- 
tion assay was performed using the above mentioned 
primers and randomly primed cDNA from RBL-2H3 
cells as a template. Its product revealed a single band 
on agarose gel which matched well with the expected 
length of 629 bp (according to the mouse receptor se- 
quence). The PCR product was then subcloned into the 
plasmid vector and sequenced. Comparison of the re- 
88 
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sulting sequence with those present in the database 
showed its high homology to the mouse FcyRII (Gen/ 
EMBL M14216) (85.2%) and the rat FcyRIII (Gen/ 
EMBL M64368-70) (83.8%). However, the high homol- 
ogy with the extracellular domain of the latter one, 
contrasted with a markedly low homology in the trans- 
membranal stretch, while the mouse FcyRII was, as 
expected, almost identical in this region. These results 
strongly supported the notion that the amplified se- 
quence was that of the rat FcyRII and not the FcyRIII. 
The probe was then used to screen the RBL-2H3 
cDNA library. Six positive clones were isolated and that 
with the longest cDNA insert (1.5 kb) sequenced by the 
strategy depicted in Fig. 2a. Sequence analysis identified 
the only possible translational open reading frame (i.e. 
coding for a protein of the size close to mouse or human 
receptors). The sequence of the PCR product used as a 
probe was entirely contained within that reading frame. 
The 3’-noncoding region contains one polyadenylation 
signal (AATAAA) and a poly(A) tail of 18 nucleotides. 
The ORF of 855 nucleotides starts with initiation codon 
ATG at position 125, terminates at nucleotide 979. and 
encodes 285 amino acids. An amino-terminal signal se- 
quence of 33 amino acids was predicted [16]. This leaves 
after signal peptide cleavage a protein of 252 amino 
acids (Fig. 2b). This final protein comprises an extracel- 
lular domain of 179 residues, a transmembrane domain 
of 26 and an intracellular one of 47 amino acids. The 
EC region contains six potential N-glycosylation sites 
[17] as well as four cysteine residues that most likely 
form the two disulfide bridges (Cys-26, -68, -107, -151) 
thus generating two Ig-like domains. This is in agree- 
ment with the principal structural features of other Fc 
receptors. A search of the SwissProt database showed 
highest homology with mouse FcyRII (percent identity 
80.95) as well as with the rat FcyRIII (percent identity 
67.96). However in the latter case the homology is lim- 
ited only to the extracellular region. The TM stretch is, 
with the exception of single substitution of Thr for Ala, 
identical with the mouse homologous sequence. This 
confirms that FcyRII is single chain receptor and lacks 
sequences in its TM domain that lead to association 
with any known accessory chain. The IC domain has a 
85.5% identity on the amino acid level with the respec- 
tive mouse sequence. A search for possible consensus 
motifs in the IC domain, which could be endowed with 
signal capacity, revealed only 2 casein kinase II phos- 
phorylation sites (residues 2 15, 244). The significance of 
this finding is presently unclear. As mentioned already, 
there are, in the mouse, two isoforms of FcyRII gener- 
ated by alternative splicing of one exon (representing 47 
amino acids) in IC tail. According to the size and full 
sequence conservation of the splicing site in rat receptor 
we consider the cloned receptor to be the rat analog of 
mouse FcyRII b2 isoform. Preliminary data exclude the 
presence of the bl isoform in RBL-2H3 cells (Bocek P. 
et al., unpublished). 
4. DISCUSSION 
We have cloned and sequenced the cDNA encoding 
rat type II Fey receptor from the RBL-2H3 cell line. 
The sequence shows very high homology to its mouse 
counterpart (b2 isoform) as well as to the rat type III 
Fey receptor. Based on the complete conservation of 
the mouse splicing site sequence in the IC domain, we 
expect that a similar alternative splicing also occurs in 
the rat. High homology to the rat FcyRIII in EC do- 
mains is consistent with the patterns found in the 
mouse. Extensive homology between EC domains of the 
type II and type III Fey receptors in mouse (94% iden- 
tity) has prevented. so far, preparation of antibodies 
which would differentiate between them. However, se- 
quence homology of the EC domains of the cloned rat 
FcyRII and rat FcyRIII is rather lower (83.24% iden- 
tity). This suggests the possibility of preparing of rea- 
gents with the above properties for studies in the rat 
system. This is of particular importance in the mast cell 
case where a substantial part of current research is done 
on rat cells. Recent experiments on mouse macrophages 
and B cells have shown that certain stretches of the 
cytoplasmic domains of different FcyRII isoforms are 
responsible for triggering of distinct functions in the 
respective cell lines [ 181. Considering the high homology 
between rat and mouse FcyRII IC domains (85.5%) one 
can expect similar functions to be initiated via this re- 
ceptor in the rat. The heteromeric FcyRIII or FcERI use 
their accessory chains to initiate their signaling path- 
ways. However, signaling cascades triggered by the dis- 
tinct isoforms of FcyRII in different cell types are 
poorly understood. Studies in the cell types like mast 
cells (expressing FcRs for more than one isotype) have 
already been shown to be very informative [19,20]. We 
intend to investigate the functional role of the FcyRII 
in mast cells, particularly in relation to those initiated 
by the FceRI. 
The nucleotide sequence data reported in this paper 
will appear in the EMBL, DDBJ and GenBank Nucleo- 
tide Sequence Databases under the accession number 
x73371. 
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